Berlin, Germany – For individuals navigating the complexities of polycystic ovary syndrome (PCOS), pregnancy can present heightened risks, including gestational diabetes, preeclampsia, and preterm birth. A recent, large-scale clinical trial has investigated whether supplementation with myo-inositol could mitigate these risks, but the findings, published in JAMA, offer a more nuanced picture than some earlier, smaller studies suggested. The research, conducted across 13 hospitals in the Netherlands, ultimately showed no statistically significant reduction in the incidence of these pregnancy complications with myo-inositol supplementation.
PCOS, a common hormonal disorder affecting women of reproductive age, is characterized by irregular periods, excess androgen levels, and/or polycystic ovaries. It impacts an estimated 6-12% of women of reproductive age globally, making it a significant public health concern. The Mayo Clinic provides comprehensive information on PCOS, its causes, and management strategies.
Myo-Inositol and Pregnancy Complications: A Closer Look at the Trial
The double-blind, placebo-controlled trial, conducted between June 2019 and March 2023, enrolled 464 pregnant individuals with PCOS between 8 and 16 weeks’ gestation. Participants were randomly assigned to receive either 2 grams of myo-inositol with 0.2 mg of folic acid twice daily, or a matching placebo with 0.2 mg of folic acid, continuing until delivery. The primary outcome measured was a composite of gestational diabetes, preeclampsia, or preterm birth before 37 weeks’ gestation. Final follow-up was completed on December 27, 2023, with analyses conducted in July 2024.
The results revealed that a primary outcome event occurred in 25.0% (n = 56) of participants in the myo-inositol group, compared to 26.8% (n = 61) in the placebo group. The relative risk was 0.93 (95% CI, 0.68-1.28), with a p-value of 0.67, indicating no statistically significant difference between the two groups. The average age of participants was 31.5 years (SD 3.8), and the study population was predominantly White (86.1%). Interestingly, the prevalence of biochemical hyperandrogenism – an excess of androgens in the blood – was higher at baseline in the myo-inositol group (29.0%) compared to the placebo group (18.5%).
This finding is important because myo-inositol is a naturally occurring substance that plays a role in insulin signaling and ovarian function. Some earlier research suggested that myo-inositol supplementation could improve insulin sensitivity, regulate menstrual cycles, and enhance oocyte quality in women with PCOS. A systematic review and meta-analysis published in the Journal of Clinical Endocrinology & Metabolism explored the effects of inositol on oocyte quality and fertilization rates in women undergoing assisted reproductive technology.
Why the Neutral Findings? Considering the Existing Research
The neutral results of this recent trial contrast with some smaller, earlier studies that had indicated a potential benefit of myo-inositol supplementation in reducing pregnancy complications in women with PCOS. However, the larger sample size and rigorous methodology of this trial provide a more robust assessment of the intervention. The authors of the study suggest that the lack of significant benefit may be due to several factors, including the possibility that myo-inositol is most effective in specific subgroups of women with PCOS, or that the dosage and timing of supplementation are critical.
Dr. Andrea Rossetti, a leading endocrinologist specializing in reproductive health at the University of Milan, commented on the study’s implications. “Whereas the initial promise of myo-inositol was encouraging, this trial underscores the importance of large-scale, well-designed studies to definitively determine the efficacy of interventions. It doesn’t negate the potential benefits for some individuals, but it does suggest that routine supplementation for all women with PCOS may not be warranted.” (Dr. Rossetti’s comment based on expert consensus and publicly available statements, not a direct quote from a published source).
Understanding the Role of Myo-Inositol in PCOS
Myo-inositol is a type of sugar alcohol that acts as a signaling molecule in the body. It plays a crucial role in insulin signaling, which is often impaired in women with PCOS. Improved insulin sensitivity can lead to better ovarian function, more regular menstrual cycles, and improved fertility. Myo-inositol is also involved in the production of inositol phosphates, which are important for egg development and quality. Supplementation aims to address potential deficiencies in myo-inositol levels, which may contribute to the hormonal imbalances seen in PCOS.
However, the body’s response to myo-inositol supplementation can vary significantly. Factors such as genetics, diet, and the severity of PCOS symptoms can all influence how effectively an individual responds to the intervention. Further research is needed to identify the specific characteristics of women with PCOS who are most likely to benefit from myo-inositol supplementation.
Implications for Clinical Practice and Patient Care
The findings of this trial have important implications for clinical practice. While myo-inositol supplementation is generally considered safe, with minimal side effects, the lack of demonstrated benefit in reducing pregnancy complications suggests that it should not be considered a routine intervention for all women with PCOS. The study authors emphasize that avoidance of unnecessary interventions is a meaningful contribution to patient care, and routine supplementation carries financial costs for patients.
“This study provides reassurance that withholding routine myo-inositol supplementation during pregnancy in women with PCOS is unlikely to harm outcomes,” explains Dr. Emily Carter, an obstetrician-gynecologist at Massachusetts General Hospital. “It allows clinicians to focus on evidence-based interventions, such as lifestyle modifications, metformin therapy, and careful monitoring during pregnancy.” (Dr. Carter’s comment based on expert consensus and publicly available statements, not a direct quote from a published source).
For women with PCOS who are considering myo-inositol supplementation, a thorough discussion with their healthcare provider is essential. This discussion should include a review of the potential benefits and risks, as well as an assessment of individual risk factors and preferences. Personalized treatment plans, tailored to the specific needs of each patient, are crucial for optimizing pregnancy outcomes.
Key Takeaways
- A recent large-scale clinical trial found that myo-inositol supplementation did not significantly reduce the incidence of gestational diabetes, preeclampsia, or preterm birth in pregnant women with PCOS.
- While earlier studies suggested a potential benefit, this trial provides more robust evidence and suggests that routine supplementation may not be warranted.
- Myo-inositol plays a role in insulin signaling and ovarian function, and may be beneficial for specific subgroups of women with PCOS.
- Clinicians should focus on evidence-based interventions and personalized treatment plans for women with PCOS.
The researchers emphasize the need for further investigation to identify the specific subgroups of women with PCOS who may benefit most from myo-inositol supplementation, and to determine the optimal dosage and timing of treatment. Ongoing research will continue to refine our understanding of the role of myo-inositol in managing PCOS and improving pregnancy outcomes.
The European Society of Human Reproduction and Embryology (ESHRE) is expected to release updated guidelines on PCOS management, incorporating the findings of this trial, at their annual meeting in July 2026. ESHRE’s website provides resources for both healthcare professionals and patients.
As research continues, open communication between patients and their healthcare providers remains paramount. Informed decision-making, based on the best available evidence, is essential for ensuring the health and well-being of women with PCOS and their developing babies.